• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    5/7/24 4:31:08 PM ET
    $ATPC
    $ATRA
    $BSGM
    $CLOV
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATPC alert in real time by email

    Gainers

    • Clover Health Investments (NASDAQ:CLOV) shares increased by 14.9% to $0.85 during Tuesday's after-market session. The market value of their outstanding shares is at $421.4 million. The company's, Q1 earnings came out today.
    • Inogen (NASDAQ:INGN) shares increased by 13.97% to $8.32. The market value of their outstanding shares is at $195.9 million. As per the press release, Q1 earnings came out today.
    • Nektar Therapeutics (NASDAQ:NKTR) shares rose 11.92% to $1.69. The market value of their outstanding shares is at $310.3 million.
    • Agape ATP (NASDAQ:ATPC) stock increased by 8.33% to $0.26. The company's market cap stands at $20.0 million.
    • EUDA Health Holdings (NASDAQ:EUDA) stock increased by 7.99% to $1.89. The company's market cap stands at $46.5 million.
    • Atara Biotherapeutics (NASDAQ:ATRA) stock rose 7.84% to $0.65. The company's market cap stands at $78.2 million.

    Losers

    • Treace Medical Concepts (NASDAQ:TMCI) shares declined by 34.1% to $7.34 during Tuesday's after-market session. The market value of their outstanding shares is at $454.6 million. As per the news, the Q1 earnings report came out today.
    • Inspire Medical Systems (NYSE:INSP) shares fell 15.87% to $206.67. The company's market cap stands at $6.2 billion. As per the press release, Q1 earnings came out today.
    • Semler Scientific (NASDAQ:SMLR) stock declined by 15.71% to $23.73. The market value of their outstanding shares is at $166.8 million. As per the press release, Q1 earnings came out today.
    • Oragenics (AMEX:OGEN) shares fell 14.93% to $1.14. The market value of their outstanding shares is at $5.1 million.
    • BiomX (AMEX:PHGE) stock fell 12.51% to $0.35. The market value of their outstanding shares is at $19.3 million.
    • BioSig Technologies (NASDAQ:BSGM) stock declined by 8.28% to $1.22. The company's market cap stands at $13.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATPC
    $ATRA
    $BSGM
    $CLOV

    CompanyDatePrice TargetRatingAnalyst
    Nektar Therapeutics
    $NKTR
    3/24/2026$70.00Neutral
    Wedbush
    Nektar Therapeutics
    $NKTR
    3/17/2026Buy
    TD Cowen
    Inspire Medical Systems Inc.
    $INSP
    2/13/2026Outperform → Peer Perform
    Wolfe Research
    Inspire Medical Systems Inc.
    $INSP
    2/12/2026$74.00Outperform → Neutral
    Robert W. Baird
    Inspire Medical Systems Inc.
    $INSP
    2/12/2026$70.00Overweight → Equal Weight
    Wells Fargo
    Nektar Therapeutics
    $NKTR
    2/10/2026Mkt Perform → Outperform
    William Blair
    Inspire Medical Systems Inc.
    $INSP
    1/27/2026$90.00Outperform → Sector Perform
    RBC Capital Mkts
    Inspire Medical Systems Inc.
    $INSP
    1/22/2026$96.00Buy → Hold
    Truist
    More analyst ratings

    $ATPC
    $ATRA
    $BSGM
    $CLOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Nektar Therapeutics with a new price target

    Wedbush initiated coverage of Nektar Therapeutics with a rating of Neutral and set a new price target of $70.00

    3/24/26 8:19:49 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Nektar Therapeutics

    TD Cowen initiated coverage of Nektar Therapeutics with a rating of Buy

    3/17/26 7:57:51 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inspire Medical Systems downgraded by Wolfe Research

    Wolfe Research downgraded Inspire Medical Systems from Outperform to Peer Perform

    2/13/26 8:29:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $ATPC
    $ATRA
    $BSGM
    $CLOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Hair Mark

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    4/3/26 9:00:04 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Priest Brady Patrick

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    4/3/26 4:59:27 PM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form 4 filed by Reynoso Jamie L.

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    4/3/26 4:34:43 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $ATPC
    $ATRA
    $BSGM
    $CLOV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 21, 2023 - FDA Roundup: March 21, 2023

    For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

    3/21/23 3:12:46 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $ATPC
    $ATRA
    $BSGM
    $CLOV
    SEC Filings

    View All

    BiomX Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    4/1/26 9:47:44 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Clover Health Investments Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    4/1/26 8:32:45 AM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form NT 10-K filed by Agape ATP Corporation

    NT 10-K - Agape ATP Corp (0001713210) (Filer)

    3/31/26 4:20:28 PM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    $ATPC
    $ATRA
    $BSGM
    $CLOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026

    WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board of Directors has

    4/1/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System

    NETANYA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) today announced that it has entered into an option agreement to acquire control of DFSL, a developer of proprietary LADAR (Laser Radar)–based detection systems for security, defense, and critical infrastructure applications. DFSL's LADAR technology combines laser-based sensing with proprietary AI algorithms to detect and respond to both UAV and ground-based intruders. BiomX intends to exercise the option subject to the closing of the underlying agreement and obtaining shareholder approval as necessary or consideration consisting of a combination of cash, promissory note, shares of common stock and warrants. Separat

    3/31/26 10:48:41 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that Kevin Smith, President and Chief Executive Officer, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 10:15 a.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-publi

    3/31/26 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $ATPC
    $ATRA
    $BSGM
    $CLOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Curet Myriam bought $804 worth of shares (5 units at $160.72) and sold $616 worth of shares (6 units at $102.59), decreasing direct ownership by 0.03% to 3,365 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    11/24/25 8:40:17 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Large owner Giustra Frank bought $734,725 worth of shares (178,205 units at $4.12) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    9/15/25 8:19:20 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Panacea Innovation Ltd bought $670,422 worth of shares (55,000 units at $12.19) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    8/19/25 8:15:04 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATPC
    $ATRA
    $BSGM
    $CLOV
    Leadership Updates

    Live Leadership Updates

    View All

    Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026

    WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board of Directors has

    4/1/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth

    Jason Richardson Named Chief Financial Officer, Succeeding Michael Bourque Dominic Hulton Named Chief Marketing Officer Corey Moritz Appointed Vice President, U.S. Business to Business Sales Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the following leadership appointments designed to accelerate the company's next phase of growth. Jason Richardson Appointed Chief Financial Officer Jason Richardson has been appointed Chief Financial Officer, effective April 6, 2026. Mr. Richardson succeeds Michael Bourque, who will step down from his role as Chief Financial Officer on that date. M

    3/30/26 4:00:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    BiomX Adds Former Mossad Deputy to Advisory Board

    NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.  Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200

    3/30/26 9:28:34 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATPC
    $ATRA
    $BSGM
    $CLOV
    Financials

    Live finance-specific insights

    View All

    Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

    PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared to the prior year.Reported fourth quarter 2025 net loss of $(9.4) million and adjusted EBITDA of $6.2 million in the fourth quarter 2025. Reported full-year 2025 net loss of $(59.0) million c

    2/27/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance

    Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-yearAchieved industry-leading 2026 AEP growth of 53% year-over-year with strong returning member retentionExpect improving cohort economics powered by Clover Assistant to drive our first-ever full year of GAAP Net Income profitability in 2026 Financial Results: Full year 2025 Medicare Advantage membership of 113,803, up 38% year-over-yearFull year 2025 Total revenues of $1.9 billion, up 40% year-over-yearFull year 2025 GAAP Net loss of $86 million, Adjusted EBITDA of $22 million, and Adjusted Net Income of $20 million Full Year 2026 Gu

    2/26/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $ATPC
    $ATRA
    $BSGM
    $CLOV
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $ATPC
    $ATRA
    $BSGM
    $CLOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

    SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

    12/12/24 4:16:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Semler Scientific Inc.

    SC 13G - Semler Scientific, Inc. (0001554859) (Subject)

    11/26/24 12:09:40 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care